Fosamax vs Evenity (Romosozumab): Combining the Two (Rationale and Risk)

How These Two Drugs Work Differently

Alendronate binds to hydroxyapatite in bone and is ingested by osteoclasts, triggering apoptosis and reducing bone resorption. Romosozumab blocks sclerostin, a protein secreted by osteocytes that normally suppresses the Wnt signaling pathway. Blocking sclerostin does two things at once: it activates osteoblasts (bone formation goes up) and suppresses RANKL-mediated osteoclast activity (bone resorption goes down). No other approved osteoporosis drug does both simultaneously.

Alendronate: Antiresorptive Only

Alendronate has been in clinical use since FDA approval in 1995 and is covered by virtually every formulary as a generic. The standard dose is 70 mg oral once weekly. In the Fracture Intervention Trial (FIT, N=2,027), three years of alendronate reduced new vertebral fractures by 47% and hip fractures by 51% in women with existing vertebral fractures compared with placebo [1]. The drug accumulates in bone for years, which creates a residual antiresorptive effect after discontinuation but also raises long-term concerns about atypical femoral fracture after more than five years of continuous use [2].

Romosozumab: Dual-Action but Time-Limited

Romosozumab's anabolic window closes at 12 months. The FDA-approved regimen is 210 mg subcutaneously once monthly for exactly 12 injections, after which the drug is stopped regardless of response. In the FRAME trial (N=7,180), romosozumab over 12 months increased lumbar spine BMD by 13.3% and total hip BMD by 6.9% versus placebo [3]. These gains are substantially larger than the 5-8% lumbar spine increases typically seen with alendronate at 3 years [1]. After the 12-month course ends, BMD drops rapidly unless an antiresorptive is started immediately.

Why the Mechanism Gap Matters Clinically

Alendronate cannot build new bone matrix. It preserves what exists. Romosozumab builds new bone but loses its effect once the 12-month course ends. That asymmetry is the entire rationale for sequential therapy: use romosozumab to create bone, then use alendronate to defend it.

The Evidence for Sequential Romosozumab Then Alendronate

The ARCH trial (N=4,093) is the key head-to-head study comparing romosozumab followed by alendronate against alendronate alone in postmenopausal women with osteoporosis and a prior vertebral fracture [4]. At 24 months, the romosozumab-to-alendronate sequence produced 48% fewer new vertebral fractures, 27% fewer clinical fractures, and 19% fewer hip fractures compared to alendronate alone (P<0.001 for vertebral, P<0.01 for hip) [4].

What ARCH Demonstrated About Sequencing

The ARCH design had one arm start with romosozumab for 12 months and then transition to alendronate, while the other arm received alendronate for the full 24 months. The fact that a 12-month head start with romosozumab still outperformed 24 months of continuous alendronate at the 24-month endpoint tells you something specific: the anabolic burst from romosozumab, locked in by subsequent alendronate, produces a structural advantage that antiresorptive therapy alone cannot match in that timeframe [4].

The Endocrine Society's 2020 clinical practice guideline on osteoporosis states: "For patients at very high risk of fracture, treatment with an anabolic agent (teriparatide, abaloparatide, or romosozumab) is suggested before use of an antiresorptive" [5]. This sequencing preference reflects the ARCH data directly.

BMD Gains at 24 Months in ARCH

After 24 months (12 months romosozumab plus 12 months alendronate vs 24 months alendronate), lumbar spine BMD increased 14.9% in the romosozumab-to-alendronate group versus 7.1% in the alendronate-only group [4]. Total hip BMD increased 7.1% versus 3.8%, respectively [4]. These are not small differences in a disease where each 1% BMD gain correlates with measurable fracture risk reduction.

Why Starting Alendronate First Blunts Romosozumab

Prior bisphosphonate use reduces romosozumab's anabolic effect. A post-hoc analysis of the FRAME trial showed that women who had previously taken bisphosphonates had smaller bone formation marker increases in response to romosozumab than treatment-naive women [3]. The likely mechanism is that bisphosphonates suppress osteoclast activity so thoroughly that the coupling signals driving osteoblast recruitment are reduced, and romosozumab then has a smaller pool of osteoblast precursors to activate [6].

The Practical Implication

If a patient has been on alendronate for several years and you want to transition to romosozumab, a washout period is sometimes considered. However, no randomized trial has established an optimal washout duration. The American Association of Clinical Endocrinology (AACE) 2020 guidelines acknowledge this blunting effect and suggest that prior bisphosphonate use is a factor when planning anabolic therapy, though the clinical significance in terms of absolute fracture reduction remains under study [7].

Bone Turnover Markers as a Guide

Procollagen type 1 N-terminal propeptide (P1NP) is a formation marker that rises sharply within 1-3 months of starting romosozumab in treatment-naive patients. In prior bisphosphonate users, that P1NP spike is attenuated. Measuring P1NP at baseline and at 3 months into romosozumab therapy gives prescribers a practical signal of whether the anabolic window is open. A blunted or absent P1NP rise suggests the prior antiresorptive effect is interfering [6].

Cardiovascular Risk: The Romosozumab Black-Box Warning

The FDA added a black-box warning to Evenity in 2019 based on ARCH trial cardiovascular data [8]. In ARCH, the romosozumab arm had a higher rate of serious cardiovascular events (adjudicated MACE: MI, stroke, cardiovascular death) compared to the alendronate arm: 2.5% versus 1.9% over the first 12 months [4]. The absolute difference was small but statistically significant, and the mechanism is not fully understood.

Who Should Not Receive Romosozumab

The FDA label states romosozumab is contraindicated in patients who have had a myocardial infarction or stroke within the preceding 12 months [8]. Beyond that hard contraindication, clinicians should weigh the cardiovascular signal carefully in patients with established coronary artery disease, recent TIA, peripheral arterial disease, or multiple cardiovascular risk factors. The risk-benefit calculation shifts when the patient's fracture risk is extreme: a woman with a T-score of -3.5 and two prior vertebral fractures faces immediate, life-altering fracture risk that may outweigh a small incremental cardiovascular risk in the absence of recent events.

The Alendronate Cardiovascular Profile

Alendronate carries no cardiovascular warning. Some observational data suggest bisphosphonates may have a modestly favorable cardiovascular effect, though randomized trials have not confirmed a mortality benefit from this mechanism [9]. For patients with recent cardiovascular events or high cardiac risk who still need potent osteoporosis therapy, denosumab or zoledronic acid are alternatives to romosozumab that avoid the sclerostin-inhibitor cardiovascular concern [7].

Direct Comparison: Alendronate vs Romosozumab Side by Side

Efficacy

Vertebral fracture reduction vs placebo at 3 years: alendronate 47% (FIT, N=2,027) [1]. Vertebral fracture reduction vs alendronate at 24 months: romosozumab-to-alendronate sequence 48% better (ARCH, N=4,093) [4]. These numbers are not directly comparable because ARCH used an active comparator, but they illustrate that the sequential strategy outperforms antiresorptive-alone therapy in high-risk patients.

Safety Profile

Alendronate's main risks are upper GI irritation (take with 8 oz water, stay upright 30 minutes), osteonecrosis of the jaw (ONJ) at low rates in osteoporosis doses, and atypical femoral fracture after extended use [2]. Romosozumab carries ONJ and atypical femoral fracture risks similar to other osteoporosis agents, plus the cardiovascular signal [8]. Injection site reactions occur in roughly 10% of romosozumab patients but are usually mild [3].

Practical Administration

Alendronate: one tablet weekly, taken fasting with plain water, no food or other medications for 30-60 minutes afterward. Romosozumab: two subcutaneous injections of 105 mg each (delivered at the same visit for a total of 210 mg) once monthly, administered in a clinic or self-injected after training. The 12-month time limit on romosozumab means the patient and prescriber must have a clear plan for antiresorptive follow-on before the course begins.

When to Consider Switching from Fosamax to Evenity

The decision to switch hinges on fracture risk stratification. AACE defines "imminent fracture risk" as a recent fracture (within 1-2 years), T-score below -3.0, or FRAX 10-year hip fracture probability above 4.5% (the intervention threshold varies by country) [7].

Criteria That Support Switching

A patient on long-term alendronate who suffers a new fragility fracture is a clear candidate for escalation to an anabolic agent [5]. The Endocrine Society guideline specifically states that patients who fracture on antiresorptive therapy should be evaluated for anabolic escalation [5]. Other indicators include T-score decline despite alendronate adherence, very high baseline FRAX score at initial presentation, or multiple prior fractures.

Practical Transition Steps

Stop alendronate and begin romosozumab at the next scheduled visit. Some clinicians allow a brief gap (2-4 weeks) for administrative reasons, but there is no clinical need for a washout before starting romosozumab after alendronate. The concern runs in the other direction: prior alendronate may reduce the anabolic response, so documenting P1NP at baseline and at month 3 is a reasonable monitoring approach [6]. Plan the antiresorptive follow-on before the 12-month romosozumab course begins: typically alendronate 70 mg weekly resumed immediately after the last romosozumab injection, or denosumab 60 mg every 6 months as an alternative.

When Not to Switch

Patients who have had a myocardial infarction or stroke within the past year cannot receive romosozumab per the FDA label [8]. Patients who are already in the low-to-moderate fracture risk category and doing well on alendronate do not need escalation to an anabolic agent. Cost and insurance coverage are real barriers: if prior authorization for Evenity is denied and the patient's fracture risk is not extreme, continuing alendronate is a reasonable choice rather than leaving therapy gaps.

The Combination Rationale: A Framework for Sequencing Decisions

The clinical logic for combining these drugs runs in one direction only: romosozumab first, alendronate second.

Step 1. Risk stratify. Use FRAX plus DXA T-score plus clinical fracture history. Patients at very high risk (T-score <-3.0, prior fragility fracture, or FRAX hip probability above 4.5%) are candidates for anabolic-first therapy per AACE 2020 and Endocrine Society 2020 guidelines [5][7].

Step 2. Screen for cardiovascular contraindications. Ask about MI or stroke in the past 12 months. Review cardiovascular history. For patients with significant cardiac risk but no absolute contraindication, document the risk-benefit discussion in the chart.

Step 3. Start romosozumab 210 mg SC monthly for 12 months. Measure P1NP at baseline, at 3 months, and at 12 months. A P1NP rise of 40-60 mcg/L or greater at 3 months indicates active anabolic response [6].

Step 4. Transition to alendronate 70 mg weekly (or denosumab 60 mg SC every 6 months) immediately after the 12th romosozumab injection. Do not leave a gap. BMD begins declining within 6-12 months after romosozumab discontinuation without follow-on antiresorptive therapy [3].

Step 5. Repeat DXA at 24 months from romosozumab start. If BMD is stable or improving on alendronate, continue. If further decline occurs despite adherence, reassess with bone turnover markers and consider alternative antiresorptives.

Cost, Access, and Real-World Considerations

Generic alendronate 70 mg weekly costs approximately $10-15/month at most pharmacies under GoodRx pricing. Romosozumab (Evenity) costs approximately $1,800-$2,100 per monthly dose without insurance, or roughly $21,600-$25,200 for the full 12-month course [8]. Medicare Part D and most commercial plans cover Evenity with prior authorization for documented severe osteoporosis or prior fracture on therapy.

The cost gap is substantial. For patients at moderate fracture risk, the incremental clinical benefit of romosozumab over alendronate may not justify the cost. For patients at very high risk with recent fracture or T-score below -3.0, the 48% additional vertebral fracture reduction seen in ARCH represents a compelling clinical argument for the more expensive anabolic-first strategy [4].

Adherence data from real-world registry studies show that oral weekly bisphosphonate adherence at 1 year averages 50-60%, primarily because of GI side effects and the fasting requirements [9]. Monthly subcutaneous injections with romosozumab show higher short-term adherence given the 12-month fixed course, but the requirement for clinic visits or self-injection training adds its own friction.

Bone Turnover Markers: Monitoring Both Drugs

Alendronate should suppress C-terminal telopeptide (CTX), a resorption marker, by 50-70% within 3-6 months of starting therapy. If CTX remains high after 6 months, nonadherence or malabsorption (consider celiac disease) should be investigated [7].

Romosozumab should raise P1NP substantially within 3 months and simultaneously lower CTX. Both effects confirm the dual mechanism is active. If neither marker responds, check injection technique and consider whether prior bisphosphonate accumulation is limiting the anabolic response [6].

After transitioning from romosozumab to alendronate, monitor CTX at 3-6 months on alendronate to confirm adequate antiresorptive suppression. The goal is CTX below 200-280 ng/L depending on the laboratory reference range, which indicates the antiresorptive effect is protecting the bone mass gained during the romosozumab course [7].